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This study aimed to determine the effect of multidrug and toxin extrusion protein 1 (MATE1) genetic
variants on its transcript expression in peripheral blood cells. Consistent with previous in vitro ﬁndings,
MATE1 mRNA levels were signiﬁcantly higher in subjects carrying rs2453579, but not rs2252281,
compared to those without either of these promoter variants. In addition, the mRNA levels did not differ
between subjects with both variants and those with neither allele. Thus, this study reveals that the
inﬂuence of MATE1 genetic variants on its mRNA expression can be detected in vivo using peripheral
blood.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Drug transporters are major determinants of the pharmacoki-
netics, efﬁcacy and safety of drugs. They frequently have genetic
variations that result in various consequences on their expression,
mRNA stability, protein folding, intracellular localization, degra-
dation, substrate binding, and/or transport kinetics (1). These in-
ﬂuences of genetic variants in drug transporters have been
examined in vitro using Xenopus laevis oocytes and/or mammalian
cell lines, and in vivo in human pharmacokinetic and/or pharma-
codynamic studies. However, in vitro data do not always reﬂect the
ﬁndings of clinical studies, at least partly because clinical data are
also affected by other genetic, physiological and environmental
factors. In addition, species-related differences in transporter
expression and substrate speciﬁcity are not uncommon. Therefore,
it is desirable to develop a method for validating the in vitro data
directly in humans (in vivo).
Multidrug and toxin extrusion protein 1 (MATE1) is an efﬂux
drug transporter that mediates proton-coupled organic cation
secretion and is highly expressed in the kidney and liver (2,3).: þ81 285 44 7562.
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d/4.0/).Several single nucleotide polymorphisms (SNPs) of SLC47A1 (the
gene encoding MATE1), including a promoter variant -66T>C
(rs2252281), are reported to inﬂuence the glucose-lowering ac-
tivity of metformin, a typical substrate of MATE1 (4e7). Choi et al.
demonstrated that the rs2252281 variant affected the binding
potency of the transcriptional factors and reduced the reporter
activity in vitro (8). They validated the inﬂuence of the rs2252281
variant on mRNA expression of MATE1 in the surgical sections of
patient kidney samples, but failed to conﬁrm this ﬁnding in post-
mortem liver samples from another donor population. In addition,
Kim et al. showed that another common promoter variant,
-1975C>A (rs2453579), exhibited a signiﬁcant increase in reporter
activity in vitro, but that the haplotypes containing both rs2252281
and rs2453579 did not change the transcriptional activity (9). Thus,
the inﬂuence of genetic variants on MATE1 expression remains to
be conﬁrmed in vivo, albeit it is difﬁcult to conduct a clinical study
requiring kidney or liver sampling.
Recently, we found that the mRNA level of MATE1 in peripheral
blood cells before treatment with ﬂutamide is a negative predictive
biomarker for drug-induced liver injury in patients with prostate
cancer (10). In addition, MATE1 deﬁciency in mice affected the
plasma concentration of 4-nitro-3-(triﬂuoromethyl)phenylamine,
one of its major metabolites, indicating the involvement of MATE1
in the pharmacokinetics of ﬂutamide (10). Taken together, thesenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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reﬂects that in the kidney and/or liver. Therefore, the aim of the
current study was to determine whether peripheral blood samples
are useful for validating the in vitro-observed inﬂuence of genetic
variants on the transcriptional activity of SLC47A1.
The subjects and study design have been described previously in
detail (10). Brieﬂy, a venous blood sample from each of Japanese
prostate cancer patients was collected into a PAXgene™ Blood RNA
tube (BectoneDickinson and Co. Japan, Tokyo, Japan). The mRNA
levels of MATE1 and an endogenous control (glyceraldehyde 3-
phosphate dehydrogenase) were measured by real-time quantita-
tive PCR using TaqMan® Gene Expression Assays (Thermo Fisher
Scientiﬁc, Waltham, MA; assay IDs Hs00217320_m1 and
Hs99999905_m1, respectively). For this study, we obtained addi-
tional written informed consent from 35 patients. The study was
approved by the ethics committees of Jichi Medical University
(Shimotsuke, Japan) and was conducted in accordance with the
Declaration of Helsinki.
DNAwas extracted from2mL of EDTA-anticoagulated bloodusing
the TaqMan® Sample-to-SNP Kit (Thermo Fisher Scientiﬁc) accord-
ing to the manufacturer's protocol. All 35 patients were genotyped
for the promoter SNPs (rs2252281 and rs2453579) of SLC47A1 using
speciﬁc primer sets, TaqMan® probes, and a StepOnePlus™ real-
time PCR system (Thermo Fisher Scientiﬁc). The sequences for
rs2252281 were as follows: forward primer, 50-TGCGCGGTACC-
CACTG-30; reverse primer, 50-CTCAGGAGCTTCCATGTGACT-30; probe
1, 50-CCTGCGCGGTACCCA-30; and probe 2, 50-CTGCGCGGTACTCA-30.
The sequences for rs2453579 were: forward primer, 50-
CCCAGGCTGGTCTCAAAACT-30; reverse primer, 50-GCTCATGCCTA-
TAATCCCAACACTT-30; probe 1, 50-CCTGGGTTCAAGTGATC-30; and
probe 2, 50-CTGGGTTCCAGTGATC-30.
Differences among groups were analyzed using one-way anal-
ysis of variance followed by Bonferroni's post hoc test, and statis-
tical signiﬁcance was taken at P < 0.05.
The number of patients carrying promoter variants
rs2252281 T>C and rs2453579 C>Awas 8 and 14, respectively, and
none were homozygous for either variant. Consistent with the
in vitro ﬁndings reported by Kim et al. (9), the MATE1 mRNA levels
in peripheral blood cells were signiﬁcantly higher in patients car-
rying the rs2453579 A, but not the rs2252281 C allele, when
compared to those without either allele (Fig. 1). Moreover, the
MATE1 mRNA levels in carriers of both variants did not differ from
those of the non-carrier group. Thus, peripheral blood cells wereFig. 1. Comparison of SLC47A1 mRNA levels in peripheral blood cells among the ge-
notype groups of rs2252281 and rs2453579 in 35 subjects. Data represent the
mean þ SD.useful for validating the in vitro-observed inﬂuence of genetic
variants on SLC47A1 mRNA expression.
The present ﬁndings demonstrate that the haplotype in the
promoter region of SLC47A1 inﬂuences its mRNA expression in
peripheral blood cells. A previous in vitro study revealed that the
transcription factors, natural killer homeobox-2.5 and upstream
stimulating factor-1, bind to the promoter in the region of
rs2453579 C>A and enhance transcription of SLC47A1, and that the
A allele exhibits greater binding afﬁnity to both of them than the C
allele (9). On the other hand, the transcription factors, activating
protein-1 and activating protein-2 repressor, bind to the promoter
in the region of rs2252281 T>C, and the variant C allele shows
signiﬁcantly reduced promoter activity owing to decreased and
increased afﬁnities to the former and latter factors, respectively (8).
Thus, multiple promoter SNPs can simultaneously affect the tran-
scription of SLC47A1.
Although MATE1 is highly expressed and functional in the kid-
ney and liver (3), sampling of these tissues is invasive and chal-
lenging to perform in living subjects. On the other hand, peripheral
blood samples are relatively easy to obtain. MATE1 is poorly
expressed in tissues containing abundant blood cells including
bone marrow and spleen (11); however, in this study, the highly
sensitive and accurate real-time quantitative PCR method allowed
for the quantitation of MATE1 mRNA levels in peripheral blood
cells. Because most drug transporters are expressed predominantly
in tissues that are difﬁcult to obtain (e.g., small intestine, liver,
kidney, bloodebrain barrier) (1), our data demonstrate the possi-
bility that peripheral blood cells could be used for assessing the
effects of genetic variants on the mRNA expression of drug trans-
porters including MATE1.
P-glycoprotein is a drug transporter that has been studied most
thoroughly (1). Peripheral blood samples have been used to
investigate the impact of the 3435T>C variant (rs1045642) of
ABCB1 (the gene encoding P-glycoprotein) on its mRNA expression.
This synonymous SNP was reported to affect P-glycoprotein
expression levels in the duodenum (12). However, studies using
peripheral bloodmononuclear cells failed to conﬁrm the signiﬁcant
association between rs1045642 and ABCB1 mRNA expression
(13e15). This discrepancy may be due at least in part to the small
sample sizes, heterogeneity of the studied population, and/or
different experimental conditions, because ABCB1 expression may
be affected bymultiple polymorphisms and various compounds (1).
Thus, it remains to be determined whether peripheral blood cells
are useful for investigating genetic effects on mRNA expression,
even of P-glycoprotein. Additionally, the current and previous
ﬁndings present the possibility that, for such analyses, the use of
whole blood cells collected directly into a tube containing RNA
stabilization reagents is more favorable than using mononuclear
cells, which need time and isolation procedures. Further studies are
needed to address these questions.
A major limitation of the method using RNA-stabilized whole
blood samples is that it cannot be used to investigate the effect of
genetic variants on transporter function. The intronic SNPs of
SLC47A1, rs2289669 and rs8065082, are associated with an
increased response to metformin (4,5,7) but, as expected, the
mRNA levels determined in our study did not differ among the
genotype groups (data not shown). Interestingly, these intronic
SNPs were not obviously related to ﬂutamide-induced liver injury
in the patients of this study (data not shown), whereas MATE1
mRNA levels in peripheral blood cells could predict the risk (10).
Moreover, a signiﬁcant inﬂuence of the promoter variant
rs2252281 on the response to metformin has been shown even in a
small group of healthy subjects including eight homozygotes for
the variant allele (6). These ﬁndings suggest that the expression
level of MATE1 has a much greater impact on its function. Because
H. Ando et al. / Journal of Pharmacological Sciences 131 (2016) 138e140140expression of drug transporters is inﬂuenced not only by poly-
morphic variants of their genes but also by the activity of multiple
nuclear receptors, including pregnane X receptor and farnesoid X
receptor (1), transporter mRNA expression in peripheral blood cells
is also expected to be a useful non-invasive marker for evaluating
the transporter activity in other tissues.
In conclusion, MATE1 mRNA levels in peripheral blood cells
were signiﬁcantly higher in patients carrying the minor allele of
rs2453579, but not rs2252281, compared to those with other ge-
notypes. This ﬁnding suggests that peripheral blood cells are useful
for investigating the inﬂuence of genetic variants on MATE1 mRNA
expression.
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